NeoStem, Inc. Announces Geographic Expansion of Intellectual Property Coverage of AMR-001 to Canada

Published: Jun 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, June 17, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of a patent allowance in Canada. This patent is in the family titled "Compositions and Methods of Vascular Injury Repair" and protects a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction ("AMI").

Help employers find you! Check out all the jobs and post your resume.

Back to news